Novavax Terminates Settlement With GAVI Alliance For Sale Of Its COVID-19 Vaccines

• Novavax Inc (NASDAQ: NVAX) delivered a written discover to Gavi, the Vaccine Alliance, terminating with fast impact an settlement for the sale of its COVID-19 vaccine to low- and middle-income international locations.

• The corporate cited Gavi’s failure to obtain the 350 million doses it had agreed to purchase in Might final 12 months for the COVAX facility.

• The termination has not resulted in any penalties, the corporate mentioned in its regulatory submitting.

• Associated: Canada Approves Novavax’s COVID-19 Vaccine As Booster In Adults.

• Novavax obtained a non-refundable advance cost of $350 million from Gavi final 12 months and an extra $350 million this 12 months after the vaccine obtained the WHO’s emergency use itemizing, the corporate mentioned.

• As of November 18, the corporate had solely obtained orders underneath the settlement for roughly 2 million doses.

• The announcement comes on the again of poor demand for the corporate’s shot amid a world provide glut for COVID-19 vaccines and waning demand.

• Earlier this month, the corporate revised its FY22 gross sales forecast for the second time amid waning demand for COVID-19 vaccines.

• The corporate now expects annual income to be roughly $2.0 billion, the low finish of its prior forecast vary of $2 billion – $2.3 billion.

• Worth Motion: NVAX shares are up 0.63% at $19.07 premarket on the final examine Tuesday.

See extra from Benzinga

Do not miss real-time alerts in your shares – be a part of Benzinga Professional without spending a dime! Attempt the device that can provide help to make investments smarter, sooner, and higher.

© 2022 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.